| Name | Date Acquired | How Acquired | Date Sold | Purchaser Name | Gross Sales Price | Basis | Basis Method | Sales Expenses | Total (net) | Accumulated Depreciation |
|---|---|---|---|---|---|---|---|---|---|---|
| Publicly-traded Securities | 467,951 | 465,712 | 2,239 | |||||||
| Passthrough K1 Capital Gain | 130,136 |
| Identifier | Return Reference | Explanation |
|---|
| Name of Bond | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| SUREFIRE MEDICAL INC CONV TO SERIES B | 500,000 | 500,000 |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| 3769 shares of AMERICAN FUNDS CAP INCOME BUILDER A | 169,295 | 198,876 |
| 38450 shares of AMERICAN FUNDS INCOME FD OF AMERICA A | 645,314 | 694,402 |
| 7943 shares of AMERICAN GROWTH FD OF AMERICA | 159,245 | 272,858 |
| 63090 shares of ATRICURE, INC. | 83,514 | 435,321 |
| 50000 shares of BOSTON SCIENTIFIC | 264,713 | 286,500 |
| 6894 shares of CAPITAL WORLD GROWTH INCOME | 176,019 | 256,447 |
| 3454 shares of MAP PHARMACEUTICALS, INC. | 27,715 | 54,055 |
| 12500 shares of PROSHARES TRUST | 1,232,459 | 793,124 |
| 10000 shares of SIRTEX MEDICAL | 50,674 | 136,490 |
| 797 shares of XENOPORT, INC. | 8,006 | 6,193 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| ENABLE INJECTIONS, LLC | 237,485 | 237,485 | |
| ENABLE UROLOGY, LLC | 78,515 | 71,354 | |
| NEURONETICS, INC. SER. D PFD | 125,000 | 138,238 | |
| NEURONETICS, INC. SER. E PFD | 300,000 | 300,000 | |
| SKYLINE VENTURE PARTNERS III, L.P. | 5,821 | 35,152 | |
| SKYLINE VENTURE QUALIFIED PURCHASERS FD II LP | 40,065 | 6,471 | |
| SUREFIRE SERIES A PREFERRED STOCK | 805,000 | 545,930 | |
| USVP ENTREPRENEUR PARTNERS VIII-B, LP | 142,523 | 112,421 | |
| ZS PHARMA, INC. - SERIES C | 250,000 | 250,000 | |
| ZS PHARMA, INC. SER. A PFD | 100,000 | 100,000 | |
| ZUREX PHARMA, INC SERIES A PREFERRED | 200,000 | 200,000 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Administrative Fees | 31,476 | 31,476 | ||
| Bank Charges | 25 | 25 | ||
| K-1 Exp SKYLINE VENTURE PARTNERS III, L.P. | 251 | 251 | ||
| K-1 Exp SKYLINE VENTURE QUALIFIED PURCHASERS FD II LP | 47 | 47 | ||
| K-1 Exp USVP ENTREPRENEUR PARTNERS VIII-B, LP | 1,798 | 1,798 | ||
| State or Local Filing Fees | 61 | 61 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| K-1 Inc/Loss ENABLE INJECTIONS, LLC | -48,416 | -48,416 | |
| K-1 Inc/Loss ENABLE UROLOGY, LLC | -3,201 | -3,201 | |
| K-1 Inc/Loss SKYLINE VENTURE PARTNERS III, L.P. | 1 | 1 | |
| K-1 Inc/Loss USVP ENTREPRENEUR PARTNERS VIII-B, LP | 136 | 136 | |
| ASH ACESS Convertible Securities | 7,500 | 7,500 |
| Name of 501(c)(3) Organization | Balance Due |
|---|
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Philanthropic Consulting Fees | 12,000 | 12,000 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| IRS Excise Tax Payment with 1st ext 990-PF | 19,301 |